Clonidine (Equi-menoglo, Equi-migraine)
Clonidine
Equity Pharmaceutical (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Equity Pharmaceutical (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Equi-menoglo drops EACH 0,50 ml DROPS CONTAIN CLONIDINE HYDROCHLORIDE 25,0 ug | Drops | 35039935/7.1.3/0399 | Cancelled | Not determined | None |
| Equi-migraine drops EACH 0,50 ml DROPS CONTAIN CLONIDINE HYDROCHLORIDE 25,0 ug | Drops | 35040035/7.3/0400 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Clonidine
- except when intended for the prevention of migraine.
Consolidated Schedules 06 July 2026, line 3340
S2: Clonidine
- when intended for the prevention of migraine.
Consolidated Schedules 06 July 2026, line 1756
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
Drag to rotate. Structure from PubChem CID 2803.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.